Início › Sobrepeso › Arizona › Phoenix
Ensaios clínicos de Sobrepeso em Phoenix, AZ
15 estudos para Sobrepeso estão buscando participantes em locais em Phoenix e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RecrutandoFase 3
- Absolute Clinical Research, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RecrutandoFase 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RecrutandoFase 3
- Elite Clinical Studies, LLC, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RecrutandoFase 3
- Research Site, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RecrutandoFase 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RecrutandoFase 3
- AURORA-2 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RecrutandoFase 3
- AURORA-1 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RecrutandoFase 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
RecrutandoFase 3Voluntários saudáveis bem-vindos
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RecrutandoFase 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RecrutandoFase 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
RecrutandoFase 3
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
RecrutandoEstudo observacional
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
RecrutandoFase 3
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RecrutandoFase 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Ensaios de Sobrepeso em outras cidades
- San Antonio, TX33 estudos
- Houston, TX33 estudos
- Chicago, IL28 estudos
- Orlando, FL25 estudos
- Miami, FL23 estudos
- Las Vegas, NV23 estudos
- Dallas, TX20 estudos
- Atlanta, GA20 estudos
- New York City, NY19 estudos
- Jacksonville, FL19 estudos
- Washington, DC19 estudos
- Austin, TX18 estudos
Outros estudos em Phoenix
- Câncer Colorretal25 estudos
- Câncer de Mama25 estudos
- Obesidade23 estudos
- Câncer Metastático20 estudos
- Câncer de Pulmão de Não Pequenas Células20 estudos
- Insuficiência Cardíaca18 estudos
- Câncer de Pâncreas17 estudos
- Câncer (todos os tipos)17 estudos
- Câncer de Próstata17 estudos
- Mieloma Múltiplo16 estudos
- Doença Cardiovascular16 estudos
- Doença de Alzheimer15 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.